EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study

Cassidy A Gutner, Marc van der Valk, Joaquin Portilla, Eliette Jeanmaire, Leïla Belkhir, Thomas Lutz, Rebecca DeMoor, Rekha Trehan, Jenny Scherzer, Miguel Pascual-Bernáldez, Mounir Ait-Khaled, Beatriz Hernandez und 8 weitere

Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2024

DOI: 10.1177/23259582241269837 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the International Association of Providers of AIDS Care (JIAPAC), 2024. Verfasst von Cassidy A Gutner und 19 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, NC, USA. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

CARISEL is an implementation–effectiveness “hybrid” study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries.

Methods

PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted.

Results

Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores ≥4.47/5). Qualitative data supported these observations.

Conclusions

PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsAnti-HIV AgentsPyridonesHumansFemaleMaleAdultMiddle AgedEuropeHIV-1Surveys and QuestionnairesDiketopiperazines

Stichwörter der Autor:innen

acceptabilityappropriatenesscabotegravir + rilpivirinelong-actingsatisfactionstigma

Substanzen

RilpivirinecabotegravirAnti-HIV AgentsPyridonesDiketopiperazines

Autor:innen und Institutionen

  • ViiV Healthcare, Durham, NC, USA.
  • Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Hospital General Universitario Dr Balmis de Alicante, Alicante, Spain.
  • Service de Maladies Infectieuses et Tropicales, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
  • Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Infektiologikum, Frankfurt am Main, Germany.

Förderung

  • ViiV Healthcare

Zitieren

APA

Gutner, C. A., van der Valk, M., Portilla, J., Jeanmaire, E., Belkhir, L., Lutz, T., DeMoor, R., Trehan, R., Scherzer, J., Pascual-Bernáldez, M., Ait-Khaled, M., Hernandez, B., de Ruiter, A., Anand, S. B., Low, E. L., Hadi, M., Barnes, N., Sevdalis, N., Mohammed, P., & Czarnogorski, M. (2024). Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study. Journal of the International Association of Providers of AIDS Care (JIAPAC). https://doi.org/10.1177/23259582241269837

Vancouver

Gutner CA, van der Valk M, Portilla J, Jeanmaire E, Belkhir L, Lutz T, et al. Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2024. doi:10.1177/23259582241269837

BibTeX
@article{Gutner2024,
  author = {Gutner, Cassidy A and van der Valk, Marc and Portilla, Joaquin and Jeanmaire, Eliette and Belkhir, Leïla and Lutz, Thomas and DeMoor, Rebecca and Trehan, Rekha and Scherzer, Jenny and Pascual-Bernáldez, Miguel and Ait-Khaled, Mounir and Hernandez, Beatriz and de Ruiter, Annemiek and Anand, Savita Bakhshi and Low, Emma L and Hadi, Monica and Barnes, Nicola and Sevdalis, Nick and Mohammed, Perry and Czarnogorski, Maggie},
  title = {Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study},
  journal = {Journal of the International Association of Providers of AIDS Care (JIAPAC)},
  year = {2024},
  doi = {10.1177/23259582241269837}
}
Kostenlos starten →